Tags

Type your tag names separated by a space and hit enter

[Tolerance and efficacy of atovaquone-proguanil for the treatment of paediatric imported Plasmodium falciparum malaria in France: clinical practice in a university hospital in Paris].
Arch Pediatr. 2008 Mar; 15(3):245-52.AP

Abstract

Only few drugs for uncomplicated Plasmodium falciparum malaria are available in children. Atovaquone-proguanil is a recent antimalarial drug licensed in France for the uncomplicated P. falciparum malaria in adults. Few paediatric studies have evaluated atovaquone-proguanil in children for uncomplicated malaria in endemic area, but no study have evaluated this treatment for imported malaria.

OBJECTIVE

To evaluate treatment by atovaquone-proguanil for uncomplicated and imported P. falciparum malaria in children.

METHODS

We retrospectively evaluated the tolerance and the efficacy of atovaquone-proguanil in the children admitted in Robert-Debré Hospital (Paris) for a P. falciparum malaria. From January 2004 to December 2005, 48 children with a median age of 7,5 years (IQR 4-11) were treated with atovaquone-proguanil for a uncomplicated P. falciparum malaria, except for 5 children who had an isolated hyperparasitemia greater or equal to 5%.

RESULTS

Atovaquone-proguanil was stopped for 3/48 children because of vomiting. Fever resolved in all the children between Day 3 and 7, following the beginning of the treatment. One child, with a favourable outcome, had a positive parasitemia at Day 4 equal to the initial parasitemia (0,1%). No late therapeutic failure was observed among the 24 children evaluated up to one month after starting treatment.

CONCLUSION

Atovaquone-proguanil is an efficient and well-tolerated antimalarial treatment for uncomplicated P. falciparum malaria in children. The risk of vomiting should lead to a systematic initial hospitalisation of children treated with atovaquone-proguanil.

Authors+Show Affiliations

Service de pédiatrie générale, hôpital Robert-Debré, 48, boulevard Serurier, 75019 Paris, France.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

English Abstract
Journal Article

Language

fre

PubMed ID

18321692

Citation

Blondé, R, et al. "[Tolerance and Efficacy of Atovaquone-proguanil for the Treatment of Paediatric Imported Plasmodium Falciparum Malaria in France: Clinical Practice in a University Hospital in Paris]." Archives De Pediatrie : Organe Officiel De La Societe Francaise De Pediatrie, vol. 15, no. 3, 2008, pp. 245-52.
Blondé R, Naudin J, Bigirimana Z, et al. [Tolerance and efficacy of atovaquone-proguanil for the treatment of paediatric imported Plasmodium falciparum malaria in France: clinical practice in a university hospital in Paris]. Arch Pediatr. 2008;15(3):245-52.
Blondé, R., Naudin, J., Bigirimana, Z., Holvoet, L., Fenneteau, O., Vitoux, C., Bourdon, O., Angoulvant, F., Lorrot, M., D'Ortenzio, E., Bourrillon, A., Le Bras, J., Matheron, S., & Faye, A. (2008). [Tolerance and efficacy of atovaquone-proguanil for the treatment of paediatric imported Plasmodium falciparum malaria in France: clinical practice in a university hospital in Paris]. Archives De Pediatrie : Organe Officiel De La Societe Francaise De Pediatrie, 15(3), 245-52. https://doi.org/10.1016/j.arcped.2007.10.018
Blondé R, et al. [Tolerance and Efficacy of Atovaquone-proguanil for the Treatment of Paediatric Imported Plasmodium Falciparum Malaria in France: Clinical Practice in a University Hospital in Paris]. Arch Pediatr. 2008;15(3):245-52. PubMed PMID: 18321692.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - [Tolerance and efficacy of atovaquone-proguanil for the treatment of paediatric imported Plasmodium falciparum malaria in France: clinical practice in a university hospital in Paris]. AU - Blondé,R, AU - Naudin,J, AU - Bigirimana,Z, AU - Holvoet,L, AU - Fenneteau,O, AU - Vitoux,C, AU - Bourdon,O, AU - Angoulvant,F, AU - Lorrot,M, AU - D'Ortenzio,E, AU - Bourrillon,A, AU - Le Bras,J, AU - Matheron,S, AU - Faye,A, Y1 - 2008/03/05/ PY - 2007/05/05/received PY - 2007/09/23/revised PY - 2007/10/14/accepted PY - 2008/3/7/pubmed PY - 2008/8/6/medline PY - 2008/3/7/entrez SP - 245 EP - 52 JF - Archives de pediatrie : organe officiel de la Societe francaise de pediatrie JO - Arch Pediatr VL - 15 IS - 3 N2 - UNLABELLED: Only few drugs for uncomplicated Plasmodium falciparum malaria are available in children. Atovaquone-proguanil is a recent antimalarial drug licensed in France for the uncomplicated P. falciparum malaria in adults. Few paediatric studies have evaluated atovaquone-proguanil in children for uncomplicated malaria in endemic area, but no study have evaluated this treatment for imported malaria. OBJECTIVE: To evaluate treatment by atovaquone-proguanil for uncomplicated and imported P. falciparum malaria in children. METHODS: We retrospectively evaluated the tolerance and the efficacy of atovaquone-proguanil in the children admitted in Robert-Debré Hospital (Paris) for a P. falciparum malaria. From January 2004 to December 2005, 48 children with a median age of 7,5 years (IQR 4-11) were treated with atovaquone-proguanil for a uncomplicated P. falciparum malaria, except for 5 children who had an isolated hyperparasitemia greater or equal to 5%. RESULTS: Atovaquone-proguanil was stopped for 3/48 children because of vomiting. Fever resolved in all the children between Day 3 and 7, following the beginning of the treatment. One child, with a favourable outcome, had a positive parasitemia at Day 4 equal to the initial parasitemia (0,1%). No late therapeutic failure was observed among the 24 children evaluated up to one month after starting treatment. CONCLUSION: Atovaquone-proguanil is an efficient and well-tolerated antimalarial treatment for uncomplicated P. falciparum malaria in children. The risk of vomiting should lead to a systematic initial hospitalisation of children treated with atovaquone-proguanil. SN - 0929-693X UR - https://www.unboundmedicine.com/medline/citation/18321692/[Tolerance_and_efficacy_of_atovaquone_proguanil_for_the_treatment_of_paediatric_imported_Plasmodium_falciparum_malaria_in_France:_clinical_practice_in_a_university_hospital_in_Paris]_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0929-693X(07)00603-3 DB - PRIME DP - Unbound Medicine ER -